NCT02614482View on ClinicalTrials.gov

Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.

PHASE3CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

June 30, 2018

Study Completion Date

August 31, 2018

Conditions
Overactive Bladder
Interventions
DRUG

Fesoterodine

Administer medication to patients with overactive bladder

Trial Locations (1)

G1V 4G2

CHU de Québec-Université Laval, Québec

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Stéphane Bolduc

OTHER

NCT02614482 - Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children. | Biotech Hunter | Biotech Hunter